Published in final edited form as:

J Steroid Biochem Mol Biol. 2011 October ; 127(1-2): 4–8. doi:10.1016/j.jsbmb.2011.01.005.

Minireview: PPAR γ as the Target of Obesogens

Amanda Janesick¹ and Bruce Blumberg^{1,2,3}

¹ Department of Developmental and Cell Biology, 2011 Biological Sciences 3, University of California, Irvine, CA 92697-2300

² Department of Pharmaceutical Sciences, University of California, Irvine, CA

Abstract

The peroxisome proliferator-activated receptor gamma (PPAR γ) is a key regulator of adipogenesis and is medically important for its connections to obesity and the treatment of type II diabetes. Activation of this receptor by certain natural or xenobiotic compounds has been shown to stimulate adipogenesis in vitro and in vivo. Obesogens are chemicals that ultimately increase obesity through a variety of potential mechanisms, including activation of PPAR γ . The first obesogen for which a definitive mechanism of action has been elucidated is the PPAR γ and RXR activator tributyltin; however, not all chemicals that activate PPAR γ are adipogenic or correlated with obesity in humans. There are multiple mechanisms through which obesogens can target PPAR γ that may not involve direct activation of the receptor. Ligand-independent mechanisms could act through obesogen-mediated post-translational modification of PPAR γ which cause receptor de-repression or activation. PPAR γ is active in multipotent stem cells committing to the adipocyte fate during fat cell development. By modifying chromatin structure early in development, obesogens have the opportunity to influence the promoter activity of PPAR γ , or the ability of PPAR γ to bind to its target genes, ultimately biasing the progenitor pool towards the fat lineage. Obesogens that act by directly or indirectly activating PPAR γ , by increasing the levels of PPAR γ protein, or enhancing its recruitment to promoters of key genes in the adipogenic pathway may ultimately play an important role in adipogenesis and obesity.

Keywords

obesogen; obesity; adipocyte; adipogenesis; endocrine disruption; EDC; PPARgamma; nuclear receptor; stem cell; multipotent stromal stem cell; transgenerational effects; epigenetics; epigenetic reprogramming

Introduction

A major advance in the study of adipocyte development was the discovery of genes specifically expressed in mature adipocytes. Among the first to be identified was the p422 protein [1,2], later called aP2 (adipocyte protein 2) and now termed fatty acid binding protein (FABP4). Using FABP4 as a marker, it became possible to study how the differentiation of pre-adipocytes into adipocytes was regulated. Indeed, FABP4 expression is considered to be indicative of a cell committed to the adipocyte lineage [3]. An enhancer

³Corresponding Author: Blumberg@uci.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

complex, termed adipocyte regulatory factor 6 (ARF6), was soon found to drive expression of FABP4 [4]. With biochemical and mass spectrometric methods, ARF6 was characterized as a heterodimer of the nuclear receptors PPAR γ 2 and RXR [5]. The RXR-PPAR γ heterodimer is a key regulator of the adipogenic program and numerous PPAR γ target genes have been identified [reviewed in 6,7,8]. These include lipoprotein lipase (LPL), which generates non-esterified fatty acids (used in triglyceride synthesis) from lipoproteins, and aquaporin 7, which facilitates the transportation of glycerol, the backbone of triglycerides, into adipocytes [9]. During adipogenesis, PPAR γ expression is positively reinforced by CCAATT enhancer binding protein alpha (C/EBP α) [10], the activity of which is modulated by PPAR γ itself [10], glucocorticoid signaling [11], insulin signaling [12], as well as cAMP levels [13]. After the adipogenic program is initiated, insulin stimulates PPAR γ - and C/EBP α -expressing cells to accumulate/store the lipid that they produce [14].

As is the case for nearly all nuclear hormone receptors, PPAR γ can be perturbed by environmental chemicals. PPAR γ is perhaps even more susceptible than most nuclear receptors because its ligand-binding pocket is large and can accommodate a diversity of chemical structures [15]. Since PPAR γ is a master regulator of adipogenesis, a logical hypothesis is that inappropriate activation of the receptor contributes to obesity. Obesogens are chemicals, natural or xenobiotic, that promote obesity by increasing the number of fat cells, up-regulating fat storage into existing fat cells, changing the amount of calories burned at rest, shifting energy balance to favor storage of calories or altering the mechanisms through which the body regulates appetite and satiety. The first obesogen for which a definitive mechanism of action has been elucidated is the PPAR γ and RXR activator, tributyltin [16,17]. The most well known pharmaceutical obesogens, which are also agonists of PPAR γ , are the thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, used to treat type 2 diabetes. TZDs are linked to weight gain in humans [18] and increased adipogenesis in cell culture [19]. Activation of PPAR γ by TZDs increases proliferation of new fat cells, thereby reducing adipocyte hypertrophy, which has been associated with inflammation, oxidative stress, and insulin resistance [20]. Whether these newly generated adipocytes “crave” to be filled with lipid is uncertain. However, it is well established that obese humans have a higher than normal fat cell number [21]; thus the hypothesis that increased adipocyte number leads to obesity is plausible and needs to be tested.

Considering the existence of pharmaceutical obesogens such as TZDs and xenobiotic obesogens such as organotins, it is highly likely that other compounds, which can inappropriately activate PPAR γ , will be obesogenic. The topic of obesogens and their potential mechanisms of action has been extensively reviewed in recent years [22–25]. PPARs as the targets of environmental chemicals, particularly phthalates has also been recently reviewed [26–28]. Therefore, this minireview focuses on recent evidence linking endocrine disrupting chemicals to PPAR γ in particular and examines the molecular mechanisms through which they might act.

Characterizing Relationships Among Chemicals, Obesogenicity, and PPAR γ

It is currently an open question whether most or all chemicals that activate PPAR γ will ultimately be shown to be obesogenic. The ability of pharmaceutical drugs, such as the TZDs, and xenobiotic chemicals such as tributyltin, to activate PPAR γ and induce adipogenesis in vitro and in vivo is well documented [reviewed in 22,23–25] and it was recently shown that PPAR γ activation is required for the obesogenic effects of TBT [29]. Of the other known xenobiotic obesogens, phthalates are the most likely to act through PPAR γ to cause increased adipocyte conversion [27,30–32]. Phthalates are of particular concern since they are omnipresent organic chemicals that give plastics, like polyvinyl chloride

(PVC), more flexibility and durability [27]. Phthalate metabolites in human urine are correlated with increased waist diameter and body mass index in adult males [33,34] and some phthalates are PPAR γ activators [32]. However, there are currently no in vivo animal studies that address whether phthalates cause adipogenesis and obesity through PPAR γ .

Aside from organotins and phthalates, there are no other confirmed endocrine disrupting chemical ligands for PPAR γ , notwithstanding its large ligand-binding pocket. Numerous classes of chemicals that activate PPAR γ have been identified in drug discovery efforts aimed at developing new anti-diabetes drugs. An increasing number of natural products that activate PPAR γ have also been identified. Some of these activate PPAR γ and induce adipogenesis in cell models such as 3T3-L1 cells; e.g., flavanone [35], bixin [36], and emodin [37]. Others, such as the flavonoid, pseudobaptigenin (found in red clover) [38], elderberry extracts [39], the putative active component of ginseng, ginsenoside 20S-protopanaxatriol [40], carvacol (a component of thyme oil) [41] and punicic acid [42] all activate PPAR γ in reporter gene assays but have not been linked to adipogenesis and obesity. While the evidence from pharmaceutical and xenobiotic obesogens might be taken to suggest that these compounds will be obesogenic, the situation is not so simple.

Selective PPAR modulators have recently been described that are either receptor-selective or behave as agonists in some cell types but not others due to differential recruitment of coregulators to PPAR target genes [reviewed in 43,44,45]. Two such drug candidates, INT-131 and telmisartan, activate PPAR γ , yet do not appear to lead to adipogenesis or obesity (although clinical data are currently scant) [44,45]. An even more extreme example is mycophenolic acid. Mycophenolic acid was shown to inhibit adipogenesis in 3T3-L1 pre-adipocytes through a non-PPAR γ -dependent pathway; however, it was also shown to be a PPAR γ activator in the same cells [46]. Complicating the issue even further, Spiegelman and colleagues have demonstrated that a functional PPAR γ ligand-binding domain may not be required for adipogenesis in murine 3T3-L1 cells [47]; although PPAR γ activation is definitely required for adipose-derived multipotent stromal cells to differentiate into adipocytes [29]. Thus, it is not sufficient simply to test chemicals for activity on PPAR γ as a surrogate to predict adipogenic potential. Rather, biological assays in relevant cell types (e.g., multipotent stromal cells or 3T3-L1 cells) are the minimum required to infer potential for obesogenicity, irrespective of PPAR γ activation.

Obesogens and Ligand-Independent Mechanisms

One simple way for a chemical to increase the potential for adipogenesis is to increase the steady-state level of PPAR γ mRNA. For example, sildenafil (known as Viagra) promotes adipogenesis by increasing the expression of adipogenic genes, including PPAR γ through a protein kinase G-dependent mechanism [48]. While it might be possible to conclude that sildenafil is an obesogen that works by increasing PPAR γ expression, all chemicals that increase adipogenesis will inevitably result in a concomitant increase in PPAR γ expression. Thus, while a rise in PPAR γ transcript/protein levels is an auspicious event for adipogenesis, since adipogenesis does not occur without PPAR γ [49,50], it may reflect the outcome, rather than the mechanism of obesogen action. PPAR γ can be targeted by obesogens at the transcriptional level via modification of chromatin structure, thereby facilitating the expression of PPAR γ during adipogenesis (see below).

The classical model of nuclear hormone receptor activation is that in the absence of ligand, co-repressors are bound, chromatin is condensed and transcription is minimal at target genes. Ligand binding triggers a conformational change in the receptor that favors binding of co-activators and release of co-repressors, chromatin decondensation and transcriptional activation. However, nuclear receptors can also be de-repressed or activated through various

post-translational modifications (PTMs) causing active release of co-repressors in the absence of PPAR γ ligands [reviewed in 51]. Indeed, PPAR γ is already known to be post-translationally phosphorylated, SUMOylated and ubiquitinated [reviewed in 52], and may function as an unliganded receptor (or might be activated by an endogenous ligand) during adipogenesis in 3T3-L1 cells [47]. Recently, it was shown that a specific phosphorylation mark on PPAR γ , established by cyclin-dependent kinase 5 (CDK5), is associated with genes that are misregulated in diabetes in response to a high fat diet [53]. The presence or absence of PTMs on PPAR γ , such as phosphorylation, could be obesogenic if they stabilize PPAR γ protein, increase the ability of the receptor to activate transcription of adipogenic genes or regulate the ability of the receptor to interact with the transcriptional machinery. The effects of specific PTMs (e.g., phosphorylation at S112) can be cell-type specific and the physiological effects of PPAR γ PTMs are currently poorly understood; thus, this is a high priority area for future research. Whether obesogens exist that target one of the mechanisms underlying PPAR γ PTMs remains to be demonstrated, but we consider this possibility quite plausible.

Targeting PPAR γ Early During Lineage Commitment of Adipocytes

Obesogens that are studied in the 3T3-L1 cell culture model necessarily reflect the actions of PPAR γ in the context of adipocyte conversion from pre-adipocytes, since 3T3-L1 cells are already committed to the adipocyte lineage and can no longer differentiate into other tissues such as bone, cartilage, muscle, or brown fat [7]. Mature adipocytes are thought to be generated from white adipocyte precursors that are committed to the adipocyte lineage [7,54–56]. This adipocyte precursor is probably derived from multipotent stromal cells (MSCs) found in almost all fetal and adult tissues [57]. Most evidence supports the theory that MSCs are the progeny of perivascular cells that surround blood vessel walls [58,59]. A subpopulation of these stem cells expressing PPAR γ [60] and CD24 [61] resides within the stromal-vascular niche of adipose tissue. These adipose progenitors have lost expression of MSC markers [61], and exhibit increased DNA methylation at the promoters of non-adipogenic genes, and decreased methylation at adipogenic genes, thereby fostering lineage restriction [62,63]. While these cells still have the capacity to become bone, cartilage, and muscle *in vitro* [61], they differentiate almost exclusively into mature adipocytes when transplanted to nude or lipodystrophic mice [60,61]. Interestingly, these adipose progenitors are present in newborn mice [60] (which have very little fat) thus indicating that there is a population of cells, expressing PPAR γ , which are programmed towards the adipogenic lineage early in life. In adulthood, these progenitors are predicted to regenerate existing fat cells [7] about every 10 years [21].

Taken together, these findings show that PPAR γ is active early in development during the commitment phase of adipogenesis and might influence fate decisions of stem cells. As a result, PPAR γ becomes a vulnerable target of obesogens during prenatal events. The organotin compound, tributyltin (TBT), when administered to pregnant mice, will cause newborn offspring exposed, *in utero*, to develop adipocytes prematurely in the liver, testis, mammary gland and inguinal adipose tissue [17]. Adipose-derived MSCs harvested from such animals showed pronounced commitment to the adipocyte lineage compared to controls, when induced to differentiate [29]. Furthermore, adipogenesis occurred at the expense of osteogenesis, suggesting that prenatal exposure to TBT biased the stem cells towards the adipogenic lineage [29]. There are other chemicals, such as organophosphates and 4-tert-octylphenol, that alter lineage commitment in cell culture, to thwart the bone differentiation capacity of MSCs [64]. Whether their effects involve PPAR γ remains to be determined.

Chromatin Remodeling Surrounding PPAR γ : Towards the Adipogenic Lineage

Recent research has pointed to the influence of histone methylation on lineage programming in stem cells, including MSCs. Like embryonic stem cells [65,66], naïve T cells [67], and neural progenitors [68], MSCs also exhibit bivalent chromatin marks on histone H3 proteins associated with promoters of lineage specific genes [69]. For example, tri-methylation of H3 at lysine 4 (H3K4me3) is linked to activation, whereas H3K27me3 is linked to repression [65,66,70]. These opposing histone modifications are predicted to prime genes such that they can be up-regulated promptly when differentiation is induced, simply by demethylating H3K27 [65].

In adipose-derived MSCs, these bivalent marks are exhibited on the PPAR γ promoter. When differentiation is stimulated, H3K27 is demethylated completely, leaving only the activating mark on the PPAR γ promoter [69]. An obesogen could alter early programming events when these lineage-specific histone modifications are established. Moreover, the demethylases that remove the H3K27me3 marks, JMJD3 and UTX [71], could be inappropriately stimulated temporally or spatially, thereby activating PPAR γ and the adipogenic program prematurely. Perhaps the most convincing evidence that xenobiotic chemicals can alter early chromatin remodeling events is derived from rat expression microarray analysis using the common fungicide vinclozolin. Several DNA, RNA, and histone methyltransferases were shown to be altered significantly in the testes of offspring prenatally exposed to vinclozolin, compared to controls [72]. A subset of these genes remained altered in subsequent generations, despite the fact that vinclozolin exposure only occurred in F0 [72]. Whether obesogenic compounds have the same effect is currently being explored in our laboratory and elsewhere.

Modification of histones surrounding the PPAR γ promoter will poise PPAR γ for activation upon differentiation. However, PPAR γ promotes more than one differentiation process. For example, PPAR γ is expressed in monoblasts [73] and promotes macrophage differentiation [74]. While adipocytes and macrophages diverge from a common origin early in development, both share their requirement for PPAR γ . An additional layer of regulation, differential recruitment of PPAR γ to enhancer elements, is required for PPAR γ to promote a cell-specific transcriptional program. Similar to the estrogen receptor, PPAR γ has an affinity for distal and intronic regulatory regions [75]. The PPAR γ /RXR heterodimer binds to direct repeats separated by one nucleotide (DR1) with PPAR γ binding 5' to RXR [76,77]. A DR1 element itself is not indicative of a biologically relevant binding site, but the presence of enhancer-specific histone methylation increases the likelihood that a particular DR1 element may be a functional PPAR' response element [78]. Unlike the aforementioned promoter marks, active enhancers possess distinctive methylation patterns associated with mono- and di-methylated histone H3, at lysine 4 (H3K4me1, H3K4me2) [79,80]. In macrophages, there are activating H3K4me1 marks on histones associated with the enhancers of cytokine and immunity genes, linked to nearby binding of PPAR γ and the ets-factor PU1 [81,82]. These same enhancers are repressed in adipocytes, while highly induced genes are associated with adjacent PPAR γ and C/EBP α binding [83]. It is currently unknown whether PPAR γ recruits methyltransferases to the DNA, or instead whether the presence of these histone marks increases the likelihood of PPAR γ binding to the DR1 consensus. In this case, obesogens could be acting to alter the chromatin landscape such that PPAR γ preferentially is recruited to the enhancers of adipogenic genes.

Conclusions and Future Directions

There is compelling evidence to suggest that chemicals in our environment are a contributing factor in the obesity epidemic; although, the full extent to which they influence obesity in humans is unknown at present. Obesogens that act early in development and demonstrate the potential to predispose humans to obesity later in life are of particular interest in this emerging field. Since PPAR γ is a master regulator of adipocyte development, chemicals that act through PPAR γ , have been, and will continue to be a major focus of investigations into environmental obesogens. Organotins (such as tributyltin) and phthalates (such as monoethylhexylphthalate) are two classes of obesogenic compounds that target PPAR γ . There may be numerous other obesogenic chemicals that remain to be identified and this is the subject of active investigation around the world. The role of environmental chemicals in the development of obesity and diabetes has attracted sufficient interest to be the topic of an upcoming workshop aimed at summarizing the state of the art and planning the way forward that will be hosted by the National Toxicology Program in January 2011.

Although it is clear that activation of PPAR γ can lead to adipogenesis and obesity, activation of PPAR γ , per se, is insufficient to classify a compound as an obesogen since at least a few PPAR γ activators have been identified that may not be linked with obesity. Even when an obesogenic chemical is demonstrated to be a PPAR γ activator, it may not be immediately apparent how the ligand acts to increase fat cell number and lipid storage in humans and to what extent PPAR γ activation is involved or required for the obesogenic phenotype. It will be important in the future to fully understand how prenatal and early life exposure to obesogenic chemicals can program exposed individuals to gain weight and what role modulation of PPAR γ expression or activity early in life plays in this process.

In addition to direct effects of ligands on PPAR γ activation, we explored the idea of non-ligand mediated effects on PPAR γ . While it is well known that PPAR γ can be modified post-translationally, the connection to obesity is not yet fully elucidated. PPAR γ is regulated at the epigenetic level in MSCs or in precursor cells occupying the white adipose vascular niche and only recently has the role for PPAR γ in the commitment stage of adipogenesis been addressed. More and more evidence supports the existence of a group of cells expressing PPAR γ and possessing characteristic epigenetic marks that are primed to become adipocytes. Yet, we do not fully understand how obesogens perturb this process and bias stem cells towards the adipogenic lineage. Future efforts will explore whether obesogens preferentially mark PPAR γ for activation or make chromatin more accessible to PPAR γ . Ultimately, it will be important to understand how perturbation of PPAR γ by obesogens in stem cells ultimately leads to obesity in humans.

Acknowledgments

Work in the authors' laboratory was supported by a grant from the NIH R01 ES015849. A.J. is a pre-doctoral trainee of NSF IGERT DGE 0549479.

References

1. Bernlohr DA, Doering TL, Kelly TJ Jr, Lane MD. Tissue specific expression of p422 protein, a putative lipid carrier, in mouse adipocytes. *Biochem Biophys Res Commun.* 1985; 132(2):850–855. [PubMed: 2415129]
2. Bernlohr DA, Angus CW, Lane MD, Bolanowski MA, Kelly TJ Jr. Expression of specific mRNAs during adipose differentiation: identification of an mRNA encoding a homologue of myelin P2 protein. *Proc Natl Acad Sci U S A.* 1984; 81(17):5468–5472. [PubMed: 6206497]

3. Tchoukalova YD, Sarr MG, Jensen MD. Measuring committed preadipocytes in human adipose tissue from severely obese patients by using adipocyte fatty acid binding protein. *Am J Physiol Regul Integr Comp Physiol*. 2004; 287(5):R1132–1140. [PubMed: 15284082]
4. Graves RA, Tontonoz P, Spiegelman BM. Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression. *Mol Cell Biol*. 1992; 12(7):3313. [PubMed: 1620133]
5. Tontonoz P, Graves RA, Budavari AI, Erdjument-Bromage H, Lui M, Hu E, Tempst P, Spiegelman BM. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. *Nucleic Acids Res*. 1994; 22(25):5628–5634. [PubMed: 7838715]
6. Lefterova MI, Lazar MA. New developments in adipogenesis. *Trends Endocrinol Metab*. 2009; 20(3):107–114. [PubMed: 19269847]
7. Park KW, Halperin DS, Tontonoz P. Before they were fat: adipocyte progenitors. *Cell Metab*. 2008; 8(6):454–457. [PubMed: 19041761]
8. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. *Nat Rev Mol Cell Biol*. 2006; 7(12):885–896. [PubMed: 17139329]
9. Kishida K, Shimomura I, Nishizawa H, Maeda N, Kuriyama H, Kondo H, Matsuda M, Nagaretani H, Ouchi N, Hotta K, Kihara S, Kadowaki T, Funahashi T, Matsuzawa Y. Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma. *J Biol Chem*. 2001; 276(51):48572–48579. [PubMed: 11679588]
10. Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, McKeon C, Darlington GJ, Spiegelman BM. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. *Mol Cell*. 1999; 3(2):151–158. [PubMed: 10078198]
11. MacDougald OA, Cornelius P, Lin FT, Chen SS, Lane MD. Glucocorticoids reciprocally regulate expression of the CCAAT/enhancer-binding protein alpha and delta genes in 3T3-L1 adipocytes and white adipose tissue. *J Biol Chem*. 1994; 269(29):19041–19047. [PubMed: 8034662]
12. Hemati N, Ross SE, Erickson RL, Groblewski GE, MacDougald OA. Signaling pathways through which insulin regulates CCAAT/enhancer binding protein alpha (C/EBPalpha) phosphorylation and gene expression in 3T3-L1 adipocytes. Correlation with GLUT4 gene expression. *J Biol Chem*. 1997; 272(41):25913–25919. [PubMed: 9325324]
13. Tang QQ, Jiang MS, Lane MD. Repressive effect of Sp1 on the C/EBPalpha gene promoter: role in adipocyte differentiation. *Mol Cell Biol*. 1999; 19(7):4855–4865. [PubMed: 10373535]
14. Le TT, Cheng JX. Single-cell profiling reveals the origin of phenotypic variability in adipogenesis. *PLoS One*. 2009; 4(4):e5189. [PubMed: 19357775]
15. Maloney EK, Waxman DJ. trans-Activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals. *Toxicol Appl Pharmacol*. 1999; 161(2):209–218. [PubMed: 10581215]
16. Kanayama T, Kobayashi N, Mamiya S, Nakanishi T, Nishikawa J. Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor gamma/retinoid X receptor pathway. *Mol Pharmacol*. 2005; 67(3):766–774. [PubMed: 15611480]
17. Grun F, Watanabe H, Zamanian Z, Maeda L, Arima K, Cubacha R, Gardiner DM, Kanno J, Iguchi T, Blumberg B. Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. *Mol Endocrinol*. 2006; 20(9):2141–2155. [PubMed: 16613991]
18. Pratley RE. The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes. *Curr Diab Rep*. 2006; 6(1):45–46. [PubMed: 16522280]
19. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). *J Biol Chem*. 1995; 270(22):12953–12956. [PubMed: 7768881]
20. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, Curtis RK, Jimenez-Linan M, Blount M, Yeo GS, Lopez M, Seppanen-Laakso T, Ashcroft FM, Oresic M, Vidal-Puig A. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. *PLoS Genet*. 2007; 3(4):e64. [PubMed: 17465682]

21. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, Blomqvist L, Hoffstedt J, Naslund E, Britton T, Concha H, Hassan M, Ryden M, Frisen J, Arner P. Dynamics of fat cell turnover in humans. *Nature*. 2008; 453(7196):783–787. [PubMed: 18454136]
22. Grun F, Blumberg B. Endocrine disruptors as obesogens. *Mol Cell Endocrinol*. 2009; 304(1–2):19–29. [PubMed: 19433244]
23. Grun F, Blumberg B. Minireview: the case for obesogens. *Mol Endocrinol*. 2009; 23(8):1127–1134. [PubMed: 19372238]
24. Janesick, A.; Blumberg, B. The role of environmental obesogens in the obesity epidemic. In: Lustig, RH., editor. *Obesity Before Birth, Endocrine Updates 30*. Springer; New York, NY: 2010. in press
25. Janesick, A.; Blumberg, B. Adipocytes as Target Cells for Endocrine Disruption. In: Diamanti-Kandarakis, E.; Gore, AC., editors. *Endocrine Disruptors and Puberty*. Humana Press/Springer; New York, NY: 2011. in press
26. Casals-Casas C, Feige JN, Desvergne B. Interference of pollutants with PPARs: endocrine disruption meets metabolism. *Int J Obes (Lond)*. 2008; 32(Suppl 6):S53–61. [PubMed: 19079281]
27. Desvergne B, Feige JN, Casals-Casas C. PPAR-mediated activity of phthalates: A link to the obesity epidemic? *Mol Cell Endocrinol*. 2009; 304(1–2):43–48. [PubMed: 19433246]
28. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. *Prog Lipid Res*. 2006; 45(2):120–159. [PubMed: 16476485]
29. Kirchner S, Kieu T, Chow C, Casey S, Blumberg B. Prenatal exposure to the environmental obesogen tributyltin predisposes multipotent stem cells to become adipocytes. *Mol Endocrinol*. 2010; 24(3):526–539. [PubMed: 20160124]
30. Bility MT, Thompson JT, McKee RH, David RM, Butala JH, Vanden Heuvel JP, Peters JM. Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. *Toxicol Sci*. 2004; 82(1):170–182. [PubMed: 15310864]
31. Feige JN, Gelman L, Rossi D, Zoete V, Metivier R, Tudor C, Anghel SI, Grosdidier A, Lathion C, Engelborghs Y, Michielin O, Wahli W, Desvergne B. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. *J Biol Chem*. 2007; 282(26):19152–19166. [PubMed: 17468099]
32. Hurst CH, Waxman DJ. Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. *Toxicol Sci*. 2003; 74(2):297–308. [PubMed: 12805656]
33. Stahlhut RW, van Wijngaarden E, Dye TD, Cook S, Swan SH. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. *Environ Health Perspect*. 2007; 115(6):876–882. [PubMed: 17589594]
34. Hatch EE, Nelson JW, Qureshi MM, Weinberg J, Moore LL, Singer M, Webster TF. Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data 1999–2002. *Environ Health*. 2008; 7:27. [PubMed: 18522739]
35. Saito T, Abe D, Sekiya K. Flavanone exhibits PPARgamma ligand activity and enhances differentiation of 3T3-L1 adipocytes. *Biochem Biophys Res Commun*. 2009; 380(2):281–285. [PubMed: 19167359]
36. Takahashi N, Goto T, Taimatsu A, Egawa K, Katoh S, Kusudo T, Sakamoto T, Ohyan C, Lee JY, Kim YI, Uemura T, Hirai S, Kawada T. Bixin regulates mRNA expression involved in adipogenesis and enhances insulin sensitivity in 3T3-L1 adipocytes through PPARgamma activation. *Biochem Biophys Res Commun*. 2009; 390(4):1372–1376. [PubMed: 19891958]
37. Yang Y, Shang W, Zhou L, Jiang B, Jin H, Chen M. Emodin with PPARgamma ligand-binding activity promotes adipocyte differentiation and increases glucose uptake in 3T3-L1 cells. *Biochem Biophys Res Commun*. 2007; 353(2):225–230. [PubMed: 17174269]
38. Salam NK, Huang TH, Kota BP, Kim MS, Li Y, Hibbs DE. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. *Chem Biol Drug Des*. 2008; 71(1):57–70. [PubMed: 18086153]
39. Christensen KB, Petersen RK, Kristiansen K, Christensen LP. Identification of bioactive compounds from flowers of black elder (*Sambucus nigra* L.) that activate the human peroxisome

- proliferator-activated receptor (PPAR) gamma. *Phytother Res.* 2010; 24(Suppl 2):S129–132. [PubMed: 20222152]
40. Han KL, Jung MH, Sohn JH, Hwang JK. Ginsenoside 20S-protopanaxatriol (PPT) activates peroxisome proliferator-activated receptor gamma (PPARgamma) in 3T3-L1 adipocytes. *Biol Pharm Bull.* 2006; 29(1):110–113. [PubMed: 16394521]
 41. Hotta M, Nakata R, Katsukawa M, Hori K, Takahashi S, Inoue H. Carvacrol, a component of thyme oil, activates PPARalpha and gamma and suppresses COX-2 expression. *J Lipid Res.* 2010; 51(1):132–139. [PubMed: 19578162]
 42. Hontecillas R, O'Shea M, Einerhand A, Diguardo M, Bassaganya-Riera J. Activation of PPAR gamma and alpha by puniceic acid ameliorates glucose tolerance and suppresses obesity-related inflammation. *J Am Coll Nutr.* 2009; 28(2):184–195. [PubMed: 19828904]
 43. Feldman PL, Lambert MH, Henke BR. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? *Curr Top Med Chem.* 2008; 8(9):728–749. [PubMed: 18537685]
 44. Higgins LS, Mantzoros CS. The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer. *PPAR Res.* 2008(2008):936906. [PubMed: 18769500]
 45. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. *Diabetes.* 2005; 54(12):3442–3452. [PubMed: 16306360]
 46. Ubukata M, Takamori H, Ohashi M, Mitsuhashi S, Yamashita K, Asada T, Nakajima N, Matsuura N, Tsuruga M, Taki K, Magae J. Mycophenolic acid as a latent agonist of PPARgamma. *Bioorg Med Chem Lett.* 2007; 17(17):4767–4770. [PubMed: 17618115]
 47. Walkey CJ, Spiegelman BM. A functional peroxisome proliferator-activated receptor-gamma ligand-binding domain is not required for adipogenesis. *J Biol Chem.* 2008; 283(36):24290–24294. [PubMed: 18622018]
 48. Zhang X, Ji J, Yan G, Wu J, Sun X, Shen J, Jiang H, Wang H. Sildenafil promotes adipogenesis through a PKG pathway. *Biochem Biophys Res Commun.* 2010; 396(4):1054–1059. [PubMed: 20471953]
 49. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. *Mol Cell.* 1999; 4(4):611–617. [PubMed: 10549292]
 50. Hosono T, Mizuguchi H, Katayama K, Koizumi N, Kawabata K, Yamaguchi T, Nakagawa S, Watanabe Y, Mayumi T, Hayakawa T. RNA interference of PPARgamma using fiber-modified adenovirus vector efficiently suppresses preadipocyte-to-adipocyte differentiation in 3T3-L1 cells. *Gene.* 2005; 348:157–165. [PubMed: 15777692]
 51. Perissi V, Jepsen K, Glass CK, Rosenfeld MG. Deconstructing repression: evolving models of co-repressor action. *Nat Rev Genet.* 2010; 11(2):109–123. [PubMed: 20084085]
 52. van Beekum O, Fleskens V, Kalkhoven E. Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator. *Obesity (Silver Spring).* 2009; 17(2):213–219. [PubMed: 19169221]
 53. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Bluher M, Griffin PR, Spiegelman BM. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. *Nature.* 2010; 466(7305):451–456. [PubMed: 20651683]
 54. Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, Scime A, Devarakonda S, Conroe HM, Erdjument-Bromage H, Tempst P, Rudnicki MA, Beier DR, Spiegelman BM. PRDM16 controls a brown fat/skeletal muscle switch. *Nature.* 2008; 454(7207):961–967. [PubMed: 18719582]
 55. Timmons JA, Wennmalm K, Larsson O, Walden TB, Lassmann T, Petrovic N, Hamilton DL, Gimeno RE, Wahlestedt C, Baar K, Nedergaard J, Cannon B. Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages. *Proc Natl Acad Sci U S A.* 2007; 104(11):4401–4406. [PubMed: 17360536]
 56. Cornelius P, MacDougald OA, Lane MD. Regulation of adipocyte development. *Annu Rev Nutr.* 1994; 14:99–129. [PubMed: 7946535]

57. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. *J Cell Sci.* 2006; 119(Pt 11):2204–2213. [PubMed: 16684817]
58. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badylak S, Buhring HJ, Giacobino JP, Lazzari L, Huard J, Peault B. A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell.* 2008; 3(3):301–313. [PubMed: 18786417]
59. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. *Stem Cells.* 2008; 26(9):2287–2299. [PubMed: 18566331]
60. Tang W, Zeve D, Suh JM, Bosnakovski D, Kyba M, Hammer RE, Tallquist MD, Graff JM. White fat progenitor cells reside in the adipose vasculature. *Science.* 2008; 322(5901):583–586. [PubMed: 18801968]
61. Rodeheffer MS, Birsoy K, Friedman JM. Identification of white adipocyte progenitor cells in vivo. *Cell.* 2008; 135(2):240–249. [PubMed: 18835024]
62. Sorensen AL, Timoskainen S, West FD, Vekterud K, Boquest AC, Ahrlund-Richter L, Stice SL, Collas P. Lineage-Specific Promoter DNA Methylation Patterns Segregate Adult Progenitor Cell Types. *Stem Cells Dev.* 2009
63. Noer A, Sorensen AL, Boquest AC, Collas P. Stable CpG hypomethylation of adipogenic promoters in freshly isolated, cultured, and differentiated mesenchymal stem cells from adipose tissue. *Mol Biol Cell.* 2006; 17(8):3543–3556. [PubMed: 16760426]
64. Hoogduijn MJ, Rakonczay Z, Genever PG. The effects of anticholinergic insecticides on human mesenchymal stem cells. *Toxicol Sci.* 2006; 94(2):342–350. [PubMed: 16960032]
65. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell.* 2006; 125(2):315–326. [PubMed: 16630819]
66. Azuara V, Perry P, Sauer S, Spivakov M, Jorgensen HF, John RM, Gouti M, Casanova M, Warnes G, Merckenschlager M, Fisher AG. Chromatin signatures of pluripotent cell lines. *Nat Cell Biol.* 2006; 8(5):532–538. [PubMed: 16570078]
67. Wei G, Wei L, Zhu J, Zang C, Hu-Li J, Yao Z, Cui K, Kanno Y, Roh TY, Watford WT, Schones DE, Peng W, Sun HW, Paul WE, O'Shea JJ, Zhao K. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. *Immunity.* 2009; 30(1):155–167. [PubMed: 19144320]
68. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, Alvarez P, Brockman W, Kim TK, Koche RP, Lee W, Mendenhall E, O'Donovan A, Presser A, Russ C, Xie X, Meissner A, Wernig M, Jaenisch R, Nusbaum C, Lander ES, Bernstein BE. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. *Nature.* 2007; 448(7153):553–560. [PubMed: 17603471]
69. Noer A, Lindeman LC, Collas P. Histone H3 modifications associated with differentiation and long-term culture of mesenchymal adipose stem cells. *Stem Cells Dev.* 2009; 18(5):725–736. [PubMed: 18771397]
70. Roh TY, Cuddapah S, Cui K, Zhao K. The genomic landscape of histone modifications in human T cells. *Proc Natl Acad Sci U S A.* 2006; 103(43):15782–15787. [PubMed: 17043231]
71. Lan F, Bayliss PE, Rinn JL, Whetstone JR, Wang JK, Chen S, Iwase S, Alpatov R, Issaeva I, Canaani E, Roberts TM, Chang HY, Shi Y. A histone H3 lysine 27 demethylase regulates animal posterior development. *Nature.* 2007; 449(7163):689–694. [PubMed: 17851529]
72. Anway MD, Rekow SS, Skinner MK. Transgenerational epigenetic programming of the embryonic testis transcriptome. *Genomics.* 2008; 91(1):30–40. [PubMed: 18042343]
73. Greene ME, Pitts J, McCarville MA, Wang XS, Newport JA, Edelstein C, Lee F, Ghosh S, Chu S. PPARgamma: observations in the hematopoietic system. *Prostaglandins Other Lipid Mediat.* 2000; 62(1):45–73. [PubMed: 10936415]
74. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. *Cell.* 1998; 93(2):241–252. [PubMed: 9568716]

75. Nielsen R, Pedersen TA, Hagenbeek D, Moulos P, Siersbaek R, Megens E, Denissov S, Borgesen M, Francoijs KJ, Mandrup S, Stunnenberg HG. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. *Genes Dev.* 2008; 22(21):2953–2967. [PubMed: 18981474]
76. Jpenberg I, Jeannin E, Wahli W, Desvergne B. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. *J Biol Chem.* 1997; 272(32):20108–20117. [PubMed: 9242684]
77. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F. Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA. *Nature.* 2008:350–356.
78. Heintzman ND, Ren B. Finding distal regulatory elements in the human genome. *Curr Opin Genet Dev.* 2009; 19(6):541–549. [PubMed: 19854636]
79. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, Van Calcar S, Qu C, Ching KA, Wang W, Weng Z, Green RD, Crawford GE, Ren B. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. *Nat Genet.* 2007; 39(3):311–318. [PubMed: 17277777]
80. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, Stuart RK, Ching CW, Ching KA, Antosiewicz-Bourget JE, Liu H, Zhang X, Green RD, Lobanenko VV, Stewart R, Thomson JA, Crawford GE, Kellis M, Ren B. Histone modifications at human enhancers reflect global cell-type-specific gene expression. *Nature.* 2009; 459(7243):108–112. [PubMed: 19295514]
81. Lefterova MI, Steger DJ, Zhuo D, Qatanani M, Mullican SE, Tuteja G, Manduchi E, Grant GR, Lazar MA. Cell-specific determinants of peroxisome proliferator-activated receptor gamma function in adipocytes and macrophages. *Mol Cell Biol.* 2010; 30(9):2078–2089. [PubMed: 20176806]
82. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell.* 2010; 38(4):576–589. [PubMed: 20513432]
83. Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adipocyte differentiation and metabolism - Novel insights from genome-wide studies. *FEBS Lett.* 2010